What does it mean that Veregen is listed in the FDA Orange Book?
The FDA’s “Orange Book” is the Drug Products database that lists FDA-approved drugs and, for those drugs, the associated patents and exclusivities that affect when generic or “AB-rated” versions can be approved. Whether Veregen appears there means it is an FDA-approved drug product with patent/exclusivity information tied to its listed strength/dosage form. [1]
Which Veregen product is in the Orange Book?
Veregen’s Orange Book listing is specific to the FDA-approved product(s) under that brand name (including the dosage form and strength). The Orange Book entry is the place to verify the exact product and its associated listed patents/exclusivities. [1]
Where can you check Veregen’s Orange Book patents and exclusivity dates?
To find Veregen’s exact FDA Orange Book listing details—such as the listed patents and any exclusivity timelines—use the Orange Book record for Veregen. [1]
For a patent-focused, plain-language view that can be easier to scan, you can also check DrugPatentWatch for Veregen’s patent/exclusivity landscape. [2]
When do Veregen patents/exclusivity stop blocking generics?
The Orange Book is designed to show what may delay generic competition based on listed patents and FDA exclusivity. The specific “when” depends on the particular Veregen product, the patents listed for it, and the exclusivity periods shown in the record. [1]
Are there FDA-listed generics for Veregen right now?
Whether any generic versions exist and whether they are approved “under” the Orange Book listing depends on current FDA approvals and the status of patents/exclusivity tied to Veregen. The most reliable way to confirm is to review Veregen’s Orange Book listing (and any associated generic applications linked to it). [1]
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/
- https://www.drugpatentwatch.com/